Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 71 Gastrointestinal 43 Head & Neck 29 Breast 25 Genitourinary 19 Other solid neoplasm 17 Gynecologic 17 Sarcoma 10 Lymphoid 9 Dermatologic 6 Tumor-Agnostic 4 CNS 4 Plasma cell 3 Other hematologic neoplasm 2 Endocrine 2 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 19 lutetium Lu 177 dotatate 8 Octreotide 8 lanreotide 7 pasireotide 6 Temozolomide 6 Sunitinib 6 pembrolizumab 5 gallium Ga 68 dotatate 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 Sorafenib 4 Data Collection 4 Carboplatin 4 3-Iodobenzylguanidine 4 Positron-Emission Tomography 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Etoposide 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pazopanib 2 lenvatinib 2 fosbretabulin 2 fluorodopa F 18 2 cabozantinib 2 avelumab 2 arginyllysine 2 Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × durvalumab × NET × Clear all

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡